Results 251 to 260 of about 159,423 (276)

Network divergence analysis identifies adaptive gene modules and two orthogonal vulnerability axes in pancreatic cancer

Molecular Oncology, EarlyView.
Tumors contain diverse cellular states whose behavior is shaped by context‐dependent gene coordination. By comparing gene–gene relationships across biological contexts, we identify adaptive transcriptional modules that reorganize into distinct vulnerability axes.
Brian Nelson, Lyanne Delgado‐Coka, Natalia Marchenko, Luisa F. Escobar‐Hoyos, Kenneth R. Shroyer, Alisa Yurovsky, Trey Ideker, Gábor Balázsi, Thomas MacCarthy, Scott Powers   +9 more
wiley   +1 more source

Tim-3 pathway dysregulation and targeting in sepsis-induced immunosuppression. [PDF]

Eur J Med Res
Luo J, Zhang C, Chen D, Chang T, Chen S, Lin Z, Yi C, Tang ZH.   +7 more
europepmc   +1 more source

RIPK4 function interferes with melanoma cell adhesion and metastasis

Molecular Oncology, EarlyView.
RIPK4 promotes melanoma growth and spread. RIPK4 levels increase as skin lesions progress to melanoma. CRISPR/Cas9‐mediated deletion of RIPK4 causes melanoma cells to form less compact spheroids, reduces their migratory and invasive abilities and limits tumour growth and dissemination in mouse models.
Norbert Wronski, Sławomir Lasota, Ewelina Madej, Anna A. Brożyna, Małgorzata Szczygieł, Agnieszka Harazin‐Lechowska, Jan Czerbniak, Janusz Rys, Jaroslaw Czyz, Agnieszka Wolnicka‐Glubisz   +9 more
wiley   +1 more source

Dual blockades of TIM-3 and PD-1 effectively prevent hyper-progression and enhance the efficacy of anti-PD-1 therapy in high-grade serous ovarian cancer. [PDF]

Cell Death Dis
Li J, Zhou Y, Song Y, Dai G, Li X, Sun Y, Wang J, Wei R, Li F, Xi L.   +9 more
europepmc   +1 more source

Unraveling the immunomodulatory role of TIM-3 in head and neck squamous cell carcinoma: implications for targeted therapy. [PDF]

Discov Oncol
Xu S, Luo Y, He Y, Chen Y, Qin F, Hu W.
europepmc   +1 more source

Involvement of Tim-3 in Maternal-fetal Tolerance: A Review of Current Understanding. [PDF]

Int J Biol Sci
Meng X, Luo Y, Cui L, Wang S.
europepmc   +1 more source

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B. [PDF]

Clin Cancer Res
Davar D, Eroglu Z, Milhem M, Becerra C, Gutierrez M, Ribas A, Di Pace B, Wang T, Zhang H, Ghosh S, Yanamandra N, Borgovan T, Srivats S, Waszak A, Dhar A, LoRusso P.   +15 more
europepmc   +1 more source

Triple checkpoint blockade of PD-1, Tim-3, and Lag-3 enhances adoptive T cell immunotherapy in a mouse model of ovarian cancer. [PDF]

Proc Natl Acad Sci U S A
Alencar GF, Mohamed AO, Burnett MG, Jean SS, Nelson AR, Su Y, Voillet V, Bates BM, Rodgers Suarez M, Ruskin SL, Trieu L, Lam JL, Bekiranov S, Gottardo R, Greenberg PD, Anderson KG.   +15 more
europepmc   +1 more source

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A. [PDF]

Clin Cancer Res
Davar D, Eroglu Z, Pérez CL, Di Pace B, Wang T, Yanamandra N, Ghosh S, Jansen K, Dhar A, Borgovan T, Waszak A, Ribas A.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

TIM-3: An update on immunotherapy

International Immunopharmacology, 2021
T cell immunoglobulin and mucin domain 3 (TIM-3) was originally found to be expressed on the surface of Th1 cells, acting as a negative regulator and binding to the ligand galectin-9 to mediate Th1 cell the apoptosis. Recent studies have shown that TIM-3 is also expressed on other immune cells, such as macrophages, dendritic cells, and monocytes.
Lizhen, Zhao, Shaoyun, Cheng, Lin, Fan, Bei, Zhang, Shengwei, Xu   +4 more
openaire   +2 more sources